Biology of Blood and Marrow Transplantation
Volume 10, Issue 11 , Pages 743-747 , November 2004

Temporal discordance between graft-versus-leukemia and graft-versus-host responses: A strategy for the separation of graft-versus-leukemia/graft-versus-host reactivity?

  • Parameswaran Hari

      Affiliations

    • Bone Marrow Transplant Program, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
    • Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
    • ,
  • Brent Logan

      Affiliations

    • Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
    • ,
  • William R. Drobyski

      Affiliations

    • Bone Marrow Transplant Program, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
    • Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
    • Corresponding Author InformationCorrespondence and reprint requests: William R. Drobyski, MD, Bone Marrow Transplant Program, 9200 W. Wisconsin Ave., Milwaukee, WI 53226

Received 22 May 2004 ,Accepted 25 July 2004.

References 

  1. Truitt RL , Johnson BD . Principles of graft versus leukemia reactivity . Biol Blood Marrow Transplant . 1995;1:61–68
  2. Sullivan KM , Weiden PL , Storb R , et al.   Influence of acute and chronic graft versus host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia . Blood . 1989;73:1720–1728
  3. Horowitz MM , Gale RP , Sondel PM , et al.   Graft-versus-leukemia reactions after bone marrow transplantation . Blood . 1990;75:555–562
  4. Truitt TR , Shih CY , LeFever AV , Tempelis LD , Andeani M , Bortin MM . Characterization of alloimmunization-induced T lymphocytes reactive against AKR leukemia in vitro and correlation with graft versus leukemia activity in vitro . J Immunol . 1983;131:2050–2058
  5. Falkenburg JH , Wafelman AR , Joosten P , et al.   Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes . Blood . 1999;94:1201–1208
  6. Rezvani K , Grube M , Brenchley JM , et al.   Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation . Blood . 2003;102:2892–2900
  7. Kloosterboer FM , Van Luxemburg-Heijs SA , Soest RV , et al.   Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells . Leukemia . 2004;18:798–808
  8. Mutis T , Verdijk R , Schrama E , Esendam B , Brand A , Goulmy E . Feasibility of immunotherapy of relapsed leukemia with ex vivo generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens . Blood . 1999;93:2336–2341
  9. Bonnet D , Warren EH , Greenberg PD , Dick JE , Riddell SR . CD8 (+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells . Proc Natl Acad Sci U S A . 1999;96:8639–8644
  10. Marjit WA , Heemskerk MH , Kloosterboer FM , et al.   Hematopoiesis-restricted minor histocompatibility antigens HA-1 or HA-2-specific T cells can induce complete remissions of relapsed leukemia . Proc Natl Acad Sci U S A . 2003;100:2742–2747
  11. Michalek J , Collins RH , Durrani HP , et al.   Definitive separation of graft versus leukemia and graft versus host specific CD4+ T cells by virtue of their receptor beta loci sequences . Proc Natl Acad Sci U S A . 2003;100:1180–1184
  12. Crough T , Nieda M , Morton J , Bashford J , Durrant S , Nicol AJ . Donor-derived b2a2-specific T cells for immunotherapy of patients with chronic myeloid leukemia . J Immunother . 2002;25:469–475
  13. Boranic M , Tonkovic I . Time pattern of the antileukemic effect of graft-versus-host reaction in mice . Cancer Res . 1971;31:1140–1147
  14. Drobyski WR , Gendelman M , Vodanovic-Jankovic  , Gorski J . Elimination of leukemia in the absence of lethal graft versus host disease . J Immunol . 2003;170:3046–3053
  15. Burt RK , Drobyski W , Seregina T , et al.   Herpes simplex thymidine kinase gene transduced donor lymphocyte infusions for relapsed hematologic malignancies following allogeneic hematopoietic stem cell transplantation . Exp Hematol . 2003;31:903–910
  16. Hessner MJ , Roth MS , Drobyski WR , Baxter-Lowe LA . Development of a sensitive, highly controlled assay for molecular detection of the Philadelphia chromosome in patients with chronic myelogenous leukemia . Genet Anal Tech Appl . 1994;11:90–94
  17. Link CJ , Burt RK , Traynor AE , Drobyski WR . Adoptive immunotherapy for leukemia (donor lymphocytes transduced with the herpes thymidine kinase gene for remission induction) . Hum Gene Ther . 1998;9:115–134
  18. Bonini C , Ferrari G , Verzeletti S , et al.   HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia . Science . 1997;276:1719–1724
  19. Berger C , Blau CA , Huang ML , et al.   Pharmacologically regulated fas-mediated death of adoptively transferred T cells in a nonhuman primate model . Blood . 2003;103:1261–1269
  20. Thomis DC , Marktel S , Bonini C , et al.   A fas-based suicide switch in human T cells for the treatment of graft versus host disease . Blood . 2001;97:1249–1257

PII: S1083-8791(04)00397-0

doi: 10.1016/j.bbmt.2004.07.006

Biology of Blood and Marrow Transplantation
Volume 10, Issue 11 , Pages 743-747 , November 2004

Article Tools

* Image Usage & Resolution